BiotechTube

Alteplase + Unfractionated heparin + Placebo + Apixaban

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Pulmonary Embolism With Acute Cor Pulmonale

Conditions

Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction, Pulmonary Embolism Subacute Massive, Right Ventricular Dysfunction, Right Ventricular Failure

Trial Timeline

Jul 25, 2019 → Apr 5, 2020

NCT ID
NCT03988842

About Alteplase + Unfractionated heparin + Placebo + Apixaban

Alteplase + Unfractionated heparin + Placebo + Apixaban is a approved stage product being developed by Bristol Myers Squibb for Pulmonary Embolism With Acute Cor Pulmonale. The current trial status is terminated. This product is registered under clinical trial identifier NCT03988842. Target conditions include Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction.

What happened to similar drugs?

20 of 20 similar drugs in Pulmonary Embolism With Acute Cor Pulmonale were approved

Approved (20) Terminated (1) Active (0)
✅MonteplaseEisaiApproved
✅lysozyme 90 mg + PlaceboEisaiApproved
✅tadalafil and ambrisentan upfront combination therapyEli LillyApproved
✅Arformoterol tartrate + Placebo: Normal SalineSumitomo PharmaApproved
✅Arformoterol tartrate inhalation solution + TiotropiumSumitomo PharmaApproved
✅Nebulized arformoterol + SalmeterolSumitomo PharmaApproved
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03988842ApprovedTerminated

Competing Products

20 competing products in Pulmonary Embolism With Acute Cor Pulmonale

See all competitors
ProductCompanyStageHype Score
AP01Avalyn PharmaceuticalsPhase 2
32
macitentan 10 mgBML, Inc.Phase 3
32
tadalafil + tadalafilEli LillyPhase 3
40
CS1 AdministrationCereno ScientificPhase 2
29
CS1Cereno ScientificPre-clinical
24
TX000045- Dose A + TX000045- Dose B + PlaceboTectonic TherapeuticPhase 2
36
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
25
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 2
32
Satralizumab (Genetical Recombination)Chugai PharmaceuticalPhase 2
39
DS-1040b + Placebo + EnoxaparinDaiichi SankyoPhase 1/2
32
DS-9231 + PlaceboDaiichi SankyoPhase 2
27
RegadenosonAstellas PharmaPre-clinical
18
Reldesemtiv + PlaceboAstellas PharmaPhase 2
35
MonteplaseEisaiApproved
43
lysozyme 90 mg + PlaceboEisaiApproved
43
Prednisolone + VoriconazoleCiplaPhase 2/3
38
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)Eli LillyPhase 2
35
tadalafil and ambrisentan upfront combination therapyEli LillyApproved
43